Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits

Raghunandan Reddy Kura ¹, Eswar Kumar Kilari ¹, Mastan Shaik Corresp. ²

1 Pharmacology Division, Andhra University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India
2 Medical Services, Troikaa Pharmaceuticals Ltd, Ahmedabad, Gujarat, India

Corresponding Author: Mastan Shaik
Email address: shkmastan@gmail.com

Background: Concomitant drug administration is a general phenomenon in the patients with chronic diseases such as diabetes mellitus. Among the currently available oral antidiabetic drugs, gliclazide is a commonly prescribed drug considering its multiple benefits in diabetic patients. Aprepitant is a commonly prescribed antiemetic drug which is mainly metabolized by CYP3A4, reported to have modest inductive and inhibitory effects on CYP2C9 and CYP3A4, respectively. Since gliclazide is metabolized by CYP2C9 (major) and CYP3A4 (minor), it is very difficult to predict the influence of aprepitant and its metabolic interaction with gliclazide. Considering the complexity associated with the combination of aprepitant and gliclazide, this study was designed to evaluate the influence of aprepitant on the pharmacodynamics (PD) and pharmacokinetics (PK) of gliclazide in animal models. Methods: The PD interaction studies were conducted in both rodent (normal and alloxan-induced diabetic rats) and non-rodent (rabbits) animal models (n=6) while the PK interaction study was conducted in normal rabbits (n=6). An extrapolated human therapeutic oral dose of gliclazide, aprepitant and their combination were administered to rats and rabbits with 7 days washout between each treatment. For the multiple-dose interaction study, the same groups were administered with an interacting drug (aprepitant) for 7 days and then the combination of aprepitant and gliclazide on 8th day. From the collected animal blood samples, blood glucose (by Glucose-Oxidase/Peroxidase method), insulin (by ELISA method) and gliclazide concentration levels (by HPLC method) were determined. Non-compartmental PK analysis was conducted by Phoenix WinNonlin software to determine the PK parameters of gliclazide. Statistical analysis was performed by student’s paired t-test. Results: The pharmacodynamic activity (blood glucose reduction and insulin levels) of gliclazide was significantly (p<0.05) influenced by aprepitant in normal and diabetic condition without any convulsions in animals. There was a significant (p<0.05) increase in concentration levels and Area Under the Curve of gliclazide while significant (p<0.05) decrease in clearance levels of gliclazide...
in rabbits. The PK interaction with gliclazide is relatively more with the multiple dose treatment of aprepitant over single dose treatment. **Conclusion:** In combination, aprepitant significantly influenced the pharmacodynamic activity of gliclazide in animal models. Considering this, care should be taken when this combination is prescribed for the clinical benefit in diabetic patients.
Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits

Raghunandan Reddy Kura¹, Eswar Kumar Kilari¹, Mastan Shaik²*

¹Pharmacology Division, Andhra University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India

²Medical Services, Troikaa Pharmaceuticals Ltd., Ahmedabad, Gujarat, India

*Correspondence:
Mastan Shaik, PhD
Assistant General Manager – Medical Services
Troikaa Pharmaceuticals Ltd, Bodakdev, Ahmedabad-380059, India
Phone: +91-7032384747
Email: shkmastan@gmail.com; mastanshaik@troikaapharma.com
ABSTRACT

Background: Concomitant drug administration is a general phenomenon in the patients with chronic diseases such as diabetes mellitus. Among the currently available oral antidiabetic drugs, gliclazide is a commonly prescribed drug considering its multiple benefits in diabetic patients. Aprepitant is a commonly prescribed antiemetic drug which is mainly metabolized by CYP3A4, reported to have modest inductive and inhibitory effects on CYP2C9 and CYP3A4, respectively. Since gliclazide is metabolized by CYP2C9 (major) and CYP3A4 (minor), it is very difficult to predict the influence of aprepitant and its metabolic interaction with gliclazide. Considering the complexity associated with the combination of aprepitant and gliclazide, this study was designed to evaluate the influence of aprepitant on the pharmacodynamics (PD) and pharmacokinetics (PK) of gliclazide in animal models.

Methods: The PD interaction studies were conducted in both rodent (normal and alloxan-induced diabetic rats) and non-rodent (rabbits) animal models (n=6) while the PK interaction study was conducted in normal rabbits (n=6). An extrapolated human therapeutic oral dose of gliclazide, aprepitant and their combination were administered to rats and rabbits with 7 days washout between each treatment. For the multiple-dose interaction study, the same groups were administered with an interacting drug (aprepitant) for 7 days and then the combination of aprepitant and gliclazide on 8th day. From the collected animal blood samples, blood glucose (by Glucose-Oxidase/Peroxidase method), insulin (by ELISA method) and gliclazide concentration levels (by HPLC method) were determined. Non-compartmental PK analysis was conducted by Phoenix WinNonlin software to determine the PK parameters of gliclazide. Statistical analysis was performed by student's paired t-test.
Results: The pharmacodynamic activity (blood glucose reduction and insulin levels) of gliclazide was significantly (p<0.05) influenced by aprepitant in normal and diabetic condition without any convulsions in animals. There was a significant (p<0.05) increase in concentration levels and Area Under the Curve of gliclazide while significant (p<0.05) decrease in clearance levels of gliclazide in rabbits. The PK interaction with gliclazide is relatively more with the multiple dose treatment of aprepitant over single dose treatment.

Conclusion: In combination, apreitnant significantly influenced the pharmacodynamic activity of gliclazide in animal models. Considering this, care should be taken when this combination is prescribed for the clinical benefit in diabetic patients.
INTRODUCTION

Concomitant drug administration is a general phenomenon in the patients with chronic diseases such as diabetes mellitus. Despite the several benefits with concomitant drug administration, it is generally associated with increased risks of medication non-adherence, adverse drug reactions/events, and toxicity due to potential drug interactions (Peron, Ogbonna & Donohoe, 2015). Monitoring and minimizing the risk of drug-drug interactions (either pharmacodynamic or pharmacokinetic) is a common goal in drug therapy while dealing with chronic diseases (Curtis, 2006). Diabetes mellitus is among the most prevalent and morbid chronic diseases which can adversely influence the health of millions of population worldwide (Julie & John, 2017).

The prevalence of diabetes mellitus has been dramatically increased from 2005 to 2015 by 30.6% (Global Burden of Disease Study, 2015). In high risk individuals, the overall prevalence of pre- and post-operative nausea and vomiting is in the range of 30 to 80% (Bergese et al., 2012). Among the currently available oral antidiabetic drugs, gliclazide is a commonly prescribed drug considering its multiple benefits (relatively low incidence of hypoglycemia, antioxidant activity and cardiovascular benefits) in diabetic patients (Fava et al., 2002; O'Brien et al., 2000; Schernthaner, 2003; Ziegler & Drouin, 1994). Aprepitant is a potent, selective and brain-penetrant non-peptide neurokinin-1 (NK1)-receptor antagonist, widely used for the prevention of chemotherapy induced nausea and vomiting (Anna et al., 2017). Aprepitant is mainly metabolized by CYP3A4 and reported to have modest inductive and inhibitory effects on CYP2C9 and CYP3A4, respectively (Anna et al., 2017; Shadle et al., 2004).

There is a high propensity for the concomitant use of aprepitant and gliclazide in diabetic patients due to (a) high prevalence of diabetes mellitus and nausea/vomiting, (b) the recent trend to recommend aprepitant for the management of refractory diabetic gastroparesis in diabetic patients.
patients (Chong & Dhatariya, 2009; Fountoulakis et al., 2017). Since gliclazide is metabolized
(Mastan & Kumar, 2009; Satyanarayana & Kumar, 2006) by CYP2C9 (major) and CYP3A4
(minor), it is very difficult to predict the influence of aprepitant and its metabolic interaction with
gliclazide. Considering the complexity associated with the combination of aprepitant and
gliclazide, this study was designed to evaluate the influence of aprepitant on the
pharmacodynamics (PD) and pharmacokinetics (PK) of gliclazide in rodent (normal and alloxan-
induced diabetic rats) and non-rodent (rabbits) animal models.

MATERIAL AND METHODS

Materials

Aprepitant and gliclazide were gift samples from Dr. Reddy’s Laboratories (Hyderabad, India).
Glucose Kits (Span Diagnostics) were procured from a local pharmacy. Alloxan monohydrate,
orthophosphoric acid, acetonitrile, dichloromethane and other relevant analytical reagents were
procured from SD Fine Chemicals Limited, (Mumbai, India) and Loba Chemie Private Limited
(Mumbai, India).

Animals

The animals (albino rats and rabbits – both male and female) were purchased from Mahaveer
Enterprises (Hyderabad, India). For this study, the rats with 220-270 g weight and 6-8 weeks of
age, and rabbits with 1.35-1.75 Kg weight and 3 months of age were selected. Throughout the
study, animals were housed individually in polypropylene cages with specific identification
number. The experimental animals were provided with a standard autoclaved commercial diet
and filtered water ad libitum. Animals were fasted for 18 hr prior to the dosing and dietary
restrictions were followed during experimentation.
Study design

As represented in Figure 1, this study was designed considering the all important factors to correlate the preclinical results to the clinical scenario. This study plan was approved by an Institutional Animal Ethics Committee (IAEC) (Registration Number 516/01/A/CPCSEA). The study was performed as per the recommendations of the Committee for the Purpose of Control, and Supervision of Experiments on Animals (CPCSEA) guidelines.

The main steps in this study are:

1. Selection of the animal models
2. Dose selection of the experimental drugs (aprepitant and gliclazide)
3. Pharmacodynamic interaction studies in normal and diabetic rats
4. Pharmacodynamic and pharmacokinetic interaction studies in rabbits
5. Pharmacokinetic and statistical analysis

In rats and rabbits, as represented in Figure 1, the activity (PD and PK) of gliclazide was evaluated in the presence of acute (single dose administration) and successively chronic (multiple dose administration for 7 days) treatment with an interacting drug (aprepitant).

Selection of the animal models

It is well known fact that the preclinical PK/PD results from one animal model can’t be correlated directly with humans due to the existence of interspecies differences. The identification and characterization of any interaction (PD or PK) in two dissimilar species at different conditions (normal and diabetic) will certainly validate the possible existence of that interaction in humans. Hence, the selection of relevant animal models is a crucial factor in the
evaluation of drug-drug interactions. Rodents (normal and alloxan-induced diabetic rats) and non-rodents (rabbits) were selected as animal models (n=6) for this study.

**Dose selection of the experimental drugs (aprepitant and gliclazide)**

To mimic the clinical scenario, the dose of the experimental drugs was determined by extrapolating the human oral therapeutic dose (aprepitant = 125 mg; gliclazide = 80 mg) *(Summary of Product Characteristics)* to rats and rabbits based on body surface area. The human equivalent dose of aprepitant in rats and rabbits is 11.25 mg/kg b.wt and 8.75 mg/1.5 kg b.wt, respectively. The human equivalent dose of gliclazide in rabbits is 5.6 mg/1.5 kg b.wt. Based on previous studies and considering the preliminary dose effect-relationship results *(Figure 2)*, the dose of gliclazide in rats was determined as 2 mg/kg b.wt. Both gliclazide and aprepitant were administered to the respective animal groups by oral gavage *(Mastan & Kumar, 2009)*.

**Pharmacodynamic interaction studies in normal and diabetic rats**

Pharmacodynamic interaction studies were conducted in two groups (normal and alloxan-induced diabetic rats) containing 6 animals each. Diabetes in albino rats was induced by the intraperitoneal injection of alloxan monohydrate (100 & 50 mg/kg b.wt) for 2 consecutive days prior to entry into the study. Rats with a blood glucose level > 11.10 mmol/L 3 days following the injection were considered as diabetic and selected for the study *(Mastan & Kumar, 2009)*.

For a single dose interaction phase, in each group, after an acclimatization period of 5 days, an oral dose of gliclazide was administered to each group. After 7 days washout period, an oral single dose of interacting drug (aprepitant) was administered. After 7 days washout period, a combination of single dose of aprepitant and gliclazide were administered with a time interval of 30 minutes. After this single dose interaction phase, the respective animal groups were continued
for chronic treatment (multiple dose administration) with an interacting drug (aprepitant) for 7
days with a regular feeding. On 8th day, a combination of single dose of aprepitant and gliclazide
were administered with a time interval of 30 minutes.

Blood samples were collected at 0 (predose), 1, 2,3,4,6,8,10 and 12 hr from retro orbital
plexus of each rat. Blood glucose was determined from these samples by GOD/POD method and
serum insulin was determined (at 2 and 8 hr) by ELISA method (Lequin, 2005) using a
commercial kit (Mercodia) at Biological E Limited (Hyderabad, India).

Pharmacodynamic and pharmacokinetic interaction studies in rabbits
The experimental design for in rabbits is similar to the rats as detailed above. The major
difference in rabbits study is simultaneous determination of pharmacodynamic and
pharmacokinetic parameters from the blood samples which were collected at 0 (predose), 1, 2, 3,
4, 6, 8, 10, 12, 16, 20 and 24 hr from the marginal ear vein of each rabbit. Blood glucose was
determined by GOD/POD method and serum insulin was determined (at 3 hr) by ELISA method.

Pharmacokinetic and statistical analysis
Gliclazide concentration levels were determined by HPLC method (Kumar et al., 2007; Kumar
& Mastan, 2011). Non-compartmental PK analysis was conducted by Phoenix WinNonlin
software to determine the PK parameters of gliclazide. The maximum concentration ($C_{\text{max}}$) and
time for the maximum concentration ($T_{\text{max}}$) were observed values directly from the concentration
and time data of gliclazide in rabbits. The Area Under the Curve (AUC) and Area Under the
Moment Curve (AUMC) were determined by the linear trapezoidal rule. The elimination rate
constant ($K_{el}$) was determined by log-linear regression of concentration-time data during the
terminal elimination phase. The Mean Residence Time (MRT) was determined by the ratio of
AUMC and AUC. The terminal half-life of gliclazide ($t_{1/2}$) was determined by the ratio of 0.693 and $K_{el}$ (Kumar & Mastan, 2011). Statistical analysis was conducted by student's paired t-test.

RESULTS

Pharmacodynamic interaction studies in rats

Influence of aprepitant on gliclazide blood glucose reduction

The mean percent blood glucose reduction of gliclazide in presence and absence of aprepitant in normal and diabetic rats is represented in Table 1. In normal rats, gliclazide produced hypoglycemic activity with maximum biphasic glucose reduction of $36.99 \pm 2.90\%$ and $35.94 \pm 2.66\%$ at 2 and 8 hr. In diabetic rats, gliclazide produced anti-hyperglycemic activity with maximum biphasic glucose reduction of $39.83 \pm 1.54\%$ and $38.91 \pm 3.68\%$ at 2 and 8 hr. These results suggest that the blood glucose reduction with gliclazide treatment was higher in diabetic condition compared to normal condition. The maximum blood glucose reduction ($18.50 \pm 7.72\%$ in normal rats and $19.91 \pm 1.82\%$ in diabetic rats) was observed at 2 hr with the interacting drug (aprepitant) in rats. The gliclazide blood glucose reduction was significantly increased in the presence of aprepitant in normal (single vs. multiple dose treatment: at 2 hr, $52.29 \pm 6.62\%$ and $60.81 \pm 8.15\%;$ at 8 hr, $49.42 \pm 8.63\%$ and $55.44 \pm 5.57\%$) rats (Table 1). The gliclazide blood glucose reduction was significantly increased in the presence of aprepitant in diabetic (single vs. multiple dose treatment: at 2 hr, $56.36 \pm 1.87\%$ and $63.44 \pm 3.65\%;$ at 8 hr, $51.30 \pm 2.61\%$ and $56.64 \pm 2.56\%$) rats (Table 1).

Influence of aprepitant on gliclazide insulin levels

The mean insulin levels of gliclazide in presence and absence of aprepitant in normal and diabetic rats is represented in Figure 3. The insulin levels observed with gliclazide treatment
were 18.48 ± 0.24 µU/mL (at 2 hr) and 18.08 ± 0.18 µU/mL (at 8 hr) in normal rats. In diabetic rats, insulin levels observed with gliclazide treatment were 9.33 ± 1.43 µU/mL (at 2 hr) and 8.19 ± 1.24 µU/mL (at 8 hr). In normal rats, the insulin levels observed with aprepitant treatment were 17.12 ± 0.11 µU/mL and 17.0 ± 0.45 µU/mL at 2 and 8 hr, respectively. In diabetic rats, the insulin levels observed with aprepitant treatment were 7.44 ± 0.31 and 7.14 ± 0.10 at 2 and 8 hr, respectively. The insulin levels were significantly increased in the presence of aprepitant in normal (single vs. multiple dose treatment: at 2 hr, 20.22 ± 0.87 and 22.05 ± 1.05 µU/mL; at 8 hr, 19.85 ± 1.17 and 20.24 ± 1.39 µU/mL) rats (Figure 3). The insulin levels were significantly increased in the presence of aprepitant in diabetic (single vs. multiple dose treatment: at 2 hr, 11.25 ± 1.15 and 12.97 ± 0.51 µU/mL; at 8 hr, 9.09 ± 0.83 and 10.14 ± 0.90 µU/mL) rats (Figure 3).

Pharmacodynamic and pharmacokinetic interaction studies in rabbits

Influence of aprepitant on gliclazide blood glucose reduction

The pharmacodynamic interaction results summary of gliclazide and aprepitant in rabbits is represented in Table 2. In rabbits, gliclazide produced hypoglycemic activity with maximum glucose reduction of 36.65 ± 5.61% at 3 hr. The blood glucose reduction observed with aprepitant was 14.14 ± 3.11% in rabbits. The gliclazide blood glucose reduction was significantly increased in the presence of aprepitant in rabbits (single vs. multiple dose treatment: 44.62 ± 4.98% and 48.87 ± 5.17%).
Influence of aprepitant on gliclazide insulin levels

The mean insulin levels of gliclazide in presence and absence of aprepitant in rabbits is represented in Figure 3. The insulin level observed with gliclazide treatment was 13.19 ± 0.90 µU/mL at 3 hr in rabbits. The insulin level observed in rabbits with aprepitant treatment was 10.55 ± 0.25 µU/mL at 3 hr. The insulin levels were significantly increased in the presence of aprepitant in rabbits (single vs. multiple dose treatment: 14.16 ± 0.62 and 15.99 ± 0.79 µU/mL).

Influence of aprepitant on gliclazide pharmacokinetics

The mean concentration and time profile of gliclazide in presence and absence of aprepitant is represented in Figure 4. The influence of aprepitant on mean PK parameters of gliclazide is represented in Table 3. There was a significant increase in concentration levels and an alteration in the pharmacokinetic parameters (increase in $C_{\text{max}}$, AUC and MRT; decrease in clearance fraction) of gliclazide in the presence of aprepitant in rabbits.

DISCUSSION

It is well known fact that several drugs have been withdrawn from the market due to their potent drug-drug interactions (Thorir et al., 2003). Hence, an evaluation of possible mechanisms of drug-drug interactions have become a cornerstone in the effective treatment of chronic diseases in which concomitant administration of multiple drugs is a very common phenomenon.

Considering the interspecies differences, this study was carefully designed to get precise and validated results from the selected animal models. The major advantages of this study are (i) an extrapolated human oral therapeutic doses of the experimental drugs to rats and rabbits to mimic the actual clinical scenario, (ii) determined the pharmacodynamic activity (blood glucose reduction in specified time intervals and insulin estimation at the time of peak concentrations) of
gliclazide in normal and diabetic condition, (iii) obtained results from two dissimilar species (rats and rabbits) for the precise identification, characterization and validation of the interaction, (iv) determined the acute and chronic influence of aprepitant on gliclazide activity, (v) determined the mechanism of pharmacokinetic interaction between aprepitant and gliclazide.

The rats are more sensitive to gliclazide effect compared to other animals and hence relevant dose selection is very crucial in drug-drug interaction studies. Hence, based on dose-response relationship study of gliclazide, the dose (2 mg/kg b.wt) which can produce a blood glucose reduction of 30 to 35% was selected for the interaction studies in rats. The results from our dose-response relationship study are in compliance to the previous reports Satyanarayana & Kumar, 2006; Mastan & Kumar, 2009; Kumar & Mastan, 2011).

Gliclazide produced a biphasic maximum response at 2 and 8 hr in rats which is probably due to an enterohepatic circulation (biliary excretion) of gliclazide as reported in previous animal studies and humans. The biphasic blood glucose reduction was not observed in rabbits confirming that there was no enterohepatic circulation (biliary excretion) of gliclazide in rabbits which is in consistent with the published studies (Satyanarayana & Kumar, 2006; Mastan & Kumar, 2009; Kumar & Mastan, 2011). In rats and rabbits, aprepitant had shown some marginal tendency to decrease the blood glucose and strong effects on insulin levels. The possible reason for this tendency is the inhibition of substance P release by aprepitant and its eventual relation with the decrease in blood glucose level (Brown & Vale, 1976; Karagiannides et al., 2011). In combination, the pharmacodynamic activity of gliclazide was significantly influenced by aprepitant in normal and diabetic condition. From these pharmacodynamic results, it appears to be an additive effect with the concomitant administration of aprepitant and gliclazide considering the individual contribution of aprepitant on blood glucose (modest effect) and insulin (strong...
However, in pharmacokinetic study in rabbits, the gliclazide concentrations were significantly increased following the single- and multiple-dose treatment of aprepitant in rabbits. The increased concentrations and significantly altered pharmacokinetic parameters of gliclazide clearly indicate that there is a significant pharmacokinetic interaction between aprepitant and gliclazide. The increase in $C_{\text{max}}$ and AUC (bioavailability) of gliclazide in the presence of aprepitant suggesting that bioavailability of gliclazide was increased. The increase in bioavailability, increase in MRT and significant decrease in gliclazide clearance confirms the decrease in gliclazide metabolism by aprepitant. The significant inhibition of CYP3A4 by aprepitant with other drugs was reported in various studies (Loose et al., 2007; Shindorf et al., 2013; Apro et al., 2010; Majumdar et al., 2003). In general, CYP3A4 inhibition is relatively higher with chronic administration of a drug and this phenomenon is reflected in our study (increase in concentrations, bioavailability and MRT, and, decrease in clearance of gliclazide). The possible mechanism of interaction is inhibition of CYP3A4 by aprepitant resulted in decrease in gliclazide metabolism and subsequently increases in gliclazide concentrations and bioavailability in rabbits. Overall, this study reasonably confirm that (a) the inhibition of CYP3A4 by aprepitant indeed lead to increased gliclazide concentrations and subsequently increased glucose reduction, (b) in addition, the gliclazide pharmacodynamic activity was further influenced by the individual contribution of aprepitant on blood glucose (modest effect) and insulin (strong effect) in animal models.

Despite the highlights of this study, we admit that there are some limitations. Firstly, the pharmacokinetic study was not evaluated in diabetic condition. Second, there is no concomitant drug administration with gliclazide which is common in diabetes therapy. Hence, this study warrants further study to explore these parameters.
CONCLUSION

In combination, aprepitant significantly influenced the pharmacodynamic activity of gliclazide in animal models. Considering this, care should be taken when this combination is prescribed for the clinical benefit in diabetic patients.

ACKNOWLEDGEMENTS

The authors are thankful to M/s. Dr. Reddy’s Laboratories, Hyderabad for supplying gift samples of the experimental drugs for this study.
REFERENCES

Aapro MS, Walko CM. 2010. Aprepitant: drug–drug interactions in perspective, *Annals of Oncology* 21(12):2316–2323. DOI:10.1093/annonc/mdq149.

Alvares OF, Meyer J. 1971. Current concepts of the histology of the oral mucosa. In: Squier C.A., Meyer J. (Eds.) Current concepts of the histology of the oral mucosa. Charles C. Thomas, Springfield, IL.97p.

Anna D, Julie K, Antonia C, Paiboon J. 2017. Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. *J Oncol Pharm Practice* 1–13. DOI: 10.1177/1078155216631408.

Bergese S, Viloria A, Uribe A, Antor A, Fernandez S. 2012. Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial. *Trials* 13:130. DOI:10.1186/1745-6215-13-130.

Brown M, Vale W. 1976. Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels. *Endocrinology*.98(3):819-22.

Chong K, Dhariya K. 2009. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. *Nat Rev Endocrinol* 5(5):285-288. DOI 10.1038/nrendo.2009.50

Curtis T. 2006. Drug Interactions of Medications Commonly Used in Diabetes. *Diabetes Spectrum* 19(4):202-211. DOI: 10.2337/diaspect.19.4.202.

Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, De Mattia G. 2002. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. *Diabetic Medicine* 19:752-757. DOI: 10.1046/j.1464-5491.2002.00762.x.
Fountoulakis N, Dunn J, Thomas S, Karalliedde J. 2017. Successful management of refractory diabetic gastroparesis with long-term Aprepitant treatment. *Diabetic Medicine* 34(10).

DOI: 10.1111/dme.13413.

Global Burden of Disease (GBD).2016. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years live with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 88:1545-602. DOI: 10.1016/S0140-6736(16)31678-6

Julie RI, John AJ. 2017. Increase in the Incidence of Diabetes and Its Implications. *N Engl J Med* 376:1473-1474. DOI: 10.1056/NEJMe1616575.

Karagiannides I, Bakirtzi K, Kokkotou E, Stavrakis D, Margolis, KG, Thomou T, Pothoulakis, C. 2011. Role of Substance P in the Regulation of Glucose Metabolism via Insulin Signaling-Associated Pathways. *Endocrinology* 152(12):4571–4580.

Kumar KE, Ramesh A, Yadav RS, Satyanarayana S. 2007. Determination of gliclazide in rabbit serum by RP-HPLC. *Acta Ciencia Indica Chem* 33:273–278.

Kumar KE, Mastan S. 2011. Influence of Efavirenz and Nevirapine on the Pharmacodynamics and Pharmacokinetics of Gliclazide in Rabbits. *Journal of Endocrinology and Metabolism* 1:113-124. DOI: 10.4021/jem34w.

Lequin R. 2005. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). *Clin. Chem.* 51(12): 2415–2418.

Loos WJ, de Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, Van NC,
DeBrujin P, Verweij J. 2007. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. *Cancer Chemo Pharmacol* 59:407–412.

Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg M.R, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA. 2003. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. *Clinical Pharmacology & Therapeutics* 74:150–156. DOI:10.1016/S0009-9236(03)00123-1.

Mastan S, Kumar KE. 2009. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. *Diabetology and Metabolic Syndrome* 1:15. DOI:10.1186/1758-5996-1-15

O'Brien RC, Luo M, Balazs N, Mercuri J. 2000. In vitro and in vivo antioxidant properties of gliclazide. *Journal of Diabetes Complications* 14:201-206. DOI: 10.1016/S1056-8727(00)00084-2

Peron EP, Ogbonna KC, Donohoe KL. 2015. Diabetic Medications and Polypharmacy. *Clinics in Geriatric Medicine* 31(1):17–27. DOI: 10.1016/j.cger.2014.08.017.

Satyanarayana S, Kilari EK. 2006. Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. *Mol Cell Biochem* 291(1-2):101-5. DOI: 10.1007/s11010-006-9202-y.

Schernthaner G. 2003. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. *Metabolism* 52:29-34. DOI:10.1016/S0026-0495(03)00215-4.

Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA.
2004. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. *J Clin Pharmacol* 44:215-223.

Shindorf ML, Manahan KJ, Geisler JP. 2013. The interaction of ifosfamide and aprepitant in gynecologic malignancies. *Gynecologic Oncology Case Reports* 6:34–35. DOI:10.1016/j.gynor.2013.06.002.

Thorir DB, John TC, Heidi JE, Volker F, Lawrence G, Scott G, John KS, Peter K, Gerald M, Lan N, Gondi K, James M, Obach RS, Stanley R, Amy R, Anita S, Fred S, John TS, Donald T, Jose MV, John W, Steven AW. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of america (phrma) perspective. *Drug Metabolism and Disposition* 31 (7): 815-832. DOI: 10.1124/dmd.31.7.815.

Ziegler O, Drouin P. 1994. Hemobiological properties of gliclazide. *Journal of Diabetes Complications* 8:235-239. DOI:10.1016/1056-8727(94)90050-7.
Table 1 (on next page)

Mean percent blood glucose reduction of gliclazide in presence and absence of aprepitant administration in normal and diabetic rats (n = 6)

Data is represented as mean ± SD; *2 mg/kg bd. wt; `11.25 mg/kg bd.wt; a Single dose treatment of aprepitant and single dose treatment of gliclazide; b Multiple dose treatment of aprepitant (7 days) and single dose treatment of gliclazide; ** P<0.01 compared to gliclazide group; *** P<0.001 compared to gliclazide group
| Time (hr) | Normal rats |  |  | Alloxan induced diabetic rats |  |  |
|----------|-------------|-----------------------------|---------------|-----------------------------|-----------------------------|---------------|
|          | Gliclazide\(^a\) | Aprepitant\(^c\) | Aprepitant + Gliclazide (Single dose treatment)\(^a\) | Aprepitant + Gliclazide (Multiple dose treatment)\(^b\) | Gliclazide\(^a\) | Aprepitant\(^c\) | Aprepitant + Gliclazide (Single dose treatment)\(^a\) | Aprepitant + Gliclazide (Multiple dose treatment)\(^b\) |
| 1        | 10.30 ± 3.42 | 03.31 ± 9.70 | 21.01 ± 6.54\(^**\) | 29.18 ± 5.87\(^***\) | 13.20 ± 1.71 | 07.11 ± 2.09 | 20.34 ± 1.39\(^***\) | 34.31 ± 1.52\(^***\) |
| 2        | 36.99 ± 2.90 | 18.50 ± 7.72 | 52.29 ± 6.62\(^***\) | 60.81 ± 8.15\(^***\) | 39.83 ± 1.54 | 19.91 ± 1.82 | 56.36 ± 1.87\(^***\) | 63.44 ± 3.65\(^***\) |
| 3        | 30.14 ± 5.59 | 15.84 ± 8.53 | 44.42 ± 7.46\(^**\) | 52.67 ± 6.45\(^***\) | 30.73 ± 2.75 | 15.11 ± 2.19 | 39.15 ± 2.70\(^***\) | 45.14 ± 2.25\(^***\) |
| 4        | 26.42 ± 8.73 | 14.34 ± 8.75 | 41.85 ± 5.53\(^**\) | 50.11 ± 4.93\(^***\) | 28.52 ± 2.22 | 12.16 ± 2.83 | 36.91 ± 3.20\(^***\) | 38.77 ± 3.30\(^***\) |
| 6        | 19.51 ± 9.90 | 12.78 ± 8.83 | 35.17 ± 5.71\(^**\) | 50.11 ± 5.31\(^***\) | 21.82 ± 1.20 | 10.74 ± 1.98 | 33.48 ± 2.84\(^***\) | 42.08 ± 2.84\(^***\) |
| 8        | 35.94 ± 2.66 | 11.23 ± 8.65 | 49.42 ± 8.63\(^**\) | 55.44 ± 5.57\(^***\) | 38.91 ± 3.68 | 10.70 ± 2.00 | 51.30 ± 2.61\(^***\) | 56.64 ± 2.56\(^***\) |
| 10       | 19.64 ± 8.29 | 08.63 ± 7.36 | 26.46 ± 6.97 | 37.27 ± 6.12\(^**\) | 31.68 ± 2.98 | 09.29 ± 2.77 | 36.49 ± 2.30\(^**\) | 39.92 ± 2.35\(^**\) |
| 12       | 10.40 ± 12.89 | 06.90 ± 8.02 | 20.75 ± 5.96 | 31.00 ± 5.27\(^**\) | 16.42 ± 1.85 | 06.31 ± 2.86 | 26.12 ± 2.06\(^***\) | 29.51 ± 2.07\(^***\) |

\(^a\) Single dose treatment
\(^b\) Multiple dose treatment
\(^**\) p < 0.01
\(^***\) p < 0.001
Table 2 (on next page)

Mean percent blood glucose reduction of gliclazide in presence and absence of aprepitant administration in normal rabbits (n = 6)

Data is represented as mean ± SD; *5.6 mg/1.5 kg b.wt; `8.75 mg/1.5 kg bd. wt; * Single dose treatment of aprepitant and single dose treatment of gliclazide; ^ Multiple dose treatment of aprepitant (7 days) and single dose treatment of gliclazide; * P<0.05 compared to gliclazide group; ** P<0.01 compared to gliclazide group; *** P<0.001 compared to gliclazide group.
| Time (hr) | Gliclazide | Aprepitant | Aprepitant + Gliclazide (Single dose treatment) | Aprepitant + Gliclazide (Multiple dose treatment) |
|----------|------------|------------|-----------------------------------------------|--------------------------------------------------|
| 1        | 10.45 ± 3.41 | 02.19 ± 1.12 | 08.28 ± 2.07 | 09.67 ± 1.79 |
| 2        | 19.28 ± 6.69 | 05.40 ± 1.29 | 24.08 ± 4.76 | 26.13 ± 6.55 |
| 3        | 36.65 ± 5.61 | 09.73 ± 2.50 | 44.62 ± 4.98* | 48.87 ± 5.17* |
| 4        | 23.39 ± 5.12 | 14.14 ± 3.11 | 37.89 ± 4.17*** | 41.18 ± 2.44*** |
| 6        | 17.84 ± 4.52 | 12.19 ± 2.24 | 29.47 ± 3.41*** | 34.37 ± 5.07*** |
| 8        | 12.76 ± 5.80 | 09.79 ± 2.51 | 25.12 ± 4.17** | 30.75 ± 5.50*** |
| 10       | 10.93 ± 5.39 | 08.13 ± 3.03 | 22.74 ± 4.52** | 26.93 ± 5.04*** |
| 12       | 07.63 ± 5.66 | 06.23 ± 2.33 | 17.31 ± 4.52** | 23.52 ± 5.38*** |
| 16       | 05.86 ± 4.91 | 04.38 ± 2.36 | 12.06 ± 4.80 | 19.27 ± 5.64** |
| 20       | 04.30 ± 4.51 | 02.67 ± 1.98 | 08.52 ± 5.21 | 14.84 ± 7.14* |
| 24       | 02.83 ± 4.07 | 01.54 ± 1.83 | 04.22 ± 5.33 | 11.53 ± 6.03* |
# Table 3 (on next page)

Mean pharmacokinetic parameters of gliclazide before and after aprepitant administration in normal rabbits (n = 6)

Data is expressed as mean ± SD; *5.6 mg/1.5 kg b.wt; 8.75 mg/1.5 kg bd. wt; *Single dose treatment of aprepitant and single dose treatment of gliclazide; *Multiple dose treatment of aprepitant (7 days) and single dose treatment of gliclazide Cmax =Maximum concentration; Tmax = Time to maximum concentration; CL = Clearance; Vd = Volume of distribution; T_{1/2} = Half-life; AUC = Area under the curve; MRT = Mean residence time; * P<0.05 compared to gliclazide group; ** P<0.001 compared to gliclazide group.
| Parameter       | Gliclazide               | Aprepitant           | Aprepitant + Gliclazide (Single dose treatment) |
|-----------------|--------------------------|----------------------|-------------------------------------------------|
| $C_{\text{max}}$ (ng/mL) | 360.11 ± 7.36            | 398.73 ± 7.42**      | 426.97 ± 7.62**                                |
| $T_{\text{max}}$ (hr)   | 03.0 ± 0.00              | 03.0 ± 0.00          | 03.0 ± 0.00                                    |
| CL (mL/hr)       | 0.00127 ± 0.00           | 0.00110 ± 0.00*      | 0.00094 ± 0.00**                              |
| Vd (mL)         | 0.01284 ± 0.00           | 0.01202 ± 0.00       | 0.01114 ± 0.00                                 |
| $T_{1/2}$ (hr)   | 7.12 ± 1.98              | 7.63 ± 1.38          | 8.49 ± 2.92                                    |
| AUC$_{0-24}$ (ng.hr/mL) | 3882.70 ± 125.54        | 4407.63 ± 38.71**    | 4968.08 ± 155.17**                            |
| AUC$_{0-\text{inf}}$ (ng.hr/mL) | 4419.37 ± 335.65      | 5113.23 ± 185.99*    | 6030.07 ± 793.69*                             |
| AUMC$_{0-24}$ (ng.hr/mL) | 35455.33 ± 1775.56    | 41606.67 ± 693.27**  | 47811.67 ± 2889.41**                          |
| MRT$_{0-24}$ (hr) | 9.13 ± 0.21              | 9.44 ± 0.08*         | 9.62 ± 0.29*                                   |
| MRT$_{0-\text{inf}}$ (hr) | 12.21 ± 1.72          | 12.99 ± 1.04         | 14.34 ± 3.20                                   |
Figure 1 (on next page)

Experimental design
Normal rats (N=6)
Alloxan-induced diabetic rats (N=6)
Normal rabbits (N=6)

Blood glucose determination by GOD/POD from the blood samples collected at regular time intervals
Insulin estimation by ELISA method (for rat at 2 and 8 hr) (for rabbits at 3 hr)
Determination of gliclazide concentrations using HPLC
Gliclazide concentration-time data for pharmacokinetic analysis
Pharmacokinetic analysis using Phoenix WinNonlin
Statistical analysis using Student’s paired t-test and interpretation of the data
Figure 2

The dose-effect relationship of gliclazide on blood glucose in normal rats (N = 6)

Blue = Gliclazide 1 mg/kg bd. wt.; Red = Gliclazide 2 mg/kg bd. wt.; Green = Gliclazide 4 mg/kg bd. wt.
Figure 3

Mean insulin levels of gliclazide treatment in presence and absence of aprepitant in rat and rabbits (n = 6)

Blue = Gliclazide treatment; Green = Single dose of aprepitant + Gliclazide; Pink = Multiple dose of aprepitant + Gliclazide; Yellow = Aprepitant treatment *P<0.001 compared to gliclazide group; **P<0.01 compared to gliclazide group; *P<0.05 compared to gliclazide group;
Figure 4

Mean serum gliclazide concentration-time profile of gliclazide in presence and absence of aprepitant in rabbits (n = 6)

Blue = Gliclazide treatment; Pink = Single dose of aprepitant + Gliclazide; Green = Multiple dose of gliclazide + Gliclazide